The stock's near-term direction hinges on clinical data readouts and the pace of cash burn against the ATM facility. Monitor for enrollment updates in both INVINCIBLE-3 and INVINCIBLE-4 studies, and any partnership announcements that could extend the cash runway beyond the current ~12 months at the current burn rate.
Price Chart
Executive Summary
Intensity Therapeutics reported Q2 2026 results with a net loss of $3.0M, wider than the $2.5M loss in Q2 2025, and cash burn continues with cash dropping to $9.5M from $10.2M at Q1 end. The key operational catalysts are the restart of patient enrollment in both the Phase 3 INVINCIBLE-3 sarcoma study and the Phase 2 INVINCIBLE-4 TNBC study, supported by $2.9M in ATM proceeds raised during and after Q2. However, the widening loss, lack of revenue, and reliance on a $60M ATM facility for funding keep the stock in a binary-risk, cash-runway story with no fundamental improvement.
Key Financial Metrics
Key Facts
- Net loss widened to $3.0M in Q2 2026 from $2.5M in Q2 2025.
- Cash and cash equivalents fell to $9.5M as of June 30, 2026, from $10.2M at March 31, 2026.
- Raised $1.6M net proceeds under the $60M ATM facility in Q2, plus $1.3M additional net proceeds after quarter-end.
- Patient treatment restarted in the Phase 2 INVINCIBLE-4 TNBC study in July 2026; targeting complete enrollment by end of 2027.
- Initiated activities to resume enrollment in the Phase 3 INVINCIBLE-3 sarcoma study in a limited number of U.S. sites.
- Preliminary data from 14 patients in INVINCIBLE-4 showed 71% pCR in the INT230-6 arm vs 42% in SOC alone.
- R&D expenses increased to $1.8M from $1.5M year-over-year due to resumed INVINCIBLE-3 activities.
- No revenue reported; company is a pre-revenue clinical-stage biotech.
Financial Impact
Net loss of $3.0M in Q2 2026 vs $2.5M in Q2 2025; cash burn of ~$0.7M per month based on $9.5M cash at June 30
Risk Factors
- Cash runway limited to approximately 12 months at current burn rate without additional ATM draws or partnership funding
- Dilution risk from continued use of the $60M ATM facility
- Clinical trial execution risk — both studies are restarting after pauses and face enrollment and regulatory hurdles
- No revenue and no approved products; binary outcome dependent on Phase 3 and Phase 2 data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001567264-26-000061 |
| Document: intensity-20260811.htm | 0001567264-26-000061 |
| Document: 0001567264-26-000061-index-headers.html | 0001567264-26-000061 |
| Document: 0001567264-26-000061-index.html | 0001567264-26-000061 |
| Document: 0001567264-26-000061.txt | 0001567264-26-000061 |
| 8-K Data (Synthetic) | 0001567264-26-000061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $4.29 $4.02 | ▼ −6.29% | ▼ −5.23% | $3.20 (−25.41%) |
Mar 5, 2026 33w ago | 8-K | $7.72 $5.70 | ▼ −26.17% | ▼ −22.38% | $3.20 (−58.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers